Genfit SA (GNFTF)

2.9500 0.0000 (0.00%) At close: 12:25PM EDT

Genfit SA

Parc EurasantE
885, avenue EugEne AvinEe
Loos 59120
France
33 3 20 16 40 00
https://www.genfit.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 159

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jean-Francois Mouney	Co-Founder & Chairman of the Board	385.14k	N/A	1955
Mr. M. Pascal Prigent	Chief Executive Officer	598.23k	N/A	1969
Prof. Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	N/A	N/A	1963
Mr. Thomas Baetz	Chief Financial Officer	N/A	N/A	1975
Mr. Pascal Caisey	Chief Operating Officer	N/A	N/A	1969
Dr. Meriam Kabbaj Ph.D.	Chief Technology Officer	N/A	N/A	1974
Dr. Dean W. Hum Ph.D.	Chief Scientific Officer	762.43k	N/A	1962
Mr. Jean-Christophe Marcoux	Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG	N/A	N/A	1978
Mr. Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	N/A	N/A	1971
Ms. Stefanie Magner J.D.	Chief Compliance Officer & Executive VP of International Legal Affairs	N/A	N/A	1982

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Corporate governance

Genfit SA’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 5; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.